Stivarga Approved By FDA For Advanced Gastrointestinal Stromal Tumors (GIST)

Stivarga (regorafenib), a cancer medication, has had its usage expanded to include patients suffering from advanced gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration. The drug is marketed by Bayer HealthCare Pharmaceuticals. GIST occurs when cancerous cells build up inside the gastrointestinal tract. There are between 3,000 to 6,000 new cases of GIST every year in the U.S, according to data published by the National Cancer Institute. As a multi-kinase inhibitor, Stivarga prevents cancer growth by blocking the key enzymes that make the cancer spread... via Health News from Medical News Today Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/02/stivarga-approved-by-fda-for-advanced_26.html